Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
Maansi Joshi, Joselle Cook, Kristen McCullough, Ahmad Nanaa, Naseema Gangat, James M. Foran, Hemant S. Murthy, Mohamed A. Kharfan‐Dabaja, Lisa Sproat, Jeanne Palmer, Animesh Pardanani, Ayalew Tefferi, Kebede H. Begna, Michelle Elliot, Aref Al‐Kali, Mrinal M. Patnaik, Mithun Vinod Shah, William J. Hogan, Mark R. Litzow, Hassan B. Alkhateeb
Abstract
Allogeneic hematopoietic cell transplantation (allo-HCT) is the only potentially curative treatment option available for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Despite advances in optimizing conditioning regimens, graft-vs-host-disease (GVHD) management and supportive care, post-transplant relapse remains the Achilles heel impeding long-term survival 1 . Availability of effective therapies for these patients is an urgent area of unmet need.